MedPath

Potassium

Generic Name
Potassium
Drug Type
Small Molecule
Chemical Formula
K
CAS Number
7440-09-7
Unique Ingredient Identifier
RWP5GA015D
Background

Potassium is an essential nutrient, like Calcium and Magnesium. It was identified as a shortfall nutrient by the 2015-2020 Advisory Committee of Dietary Guidelines for Americans. Many conditions and diseases interfere with normal body potassium balance, and underconsumption of potassium is one example. Hypokalemia (low potassium) or hyperkalemia (high potassium) may result, manifesting as various signs and symptoms. Some examples of potassium-related complications include life-threatening arrhythmia, neuromuscular dysfunction, diarrhea, nausea, and vomiting.

Various pharmacological preparations have been formulated to replenish potassium. They are available in an assortment of tablet, injection, and other forms, depending on the setting and condition being treated. Potassium is often a key ingredient for intravenous fluids, given to patients in clinical settings for rehydration, nutrition, and replenishment of electrolytes. Examples of potassium formulations include potassium citrate, potassium chloride, and potassium with dextrose and sodium chloride.

Indication

General uses of potassium

Potassium is indicated to treat a variety of conditions. Firstly, it used to replenish potassium that has been depleted by conditions including but not limited to malabsorption, decreased intake, or excess sodium intake. The causes of potassium deficiency are numerous. The following indications for potassium are not comprehensive, but include the main indications for which this nutrient is used. Various products and preparations contain potassium.

Potassium chloride

Potassium chloride is one of the main preparations of potassium used in a clinical setting. The oral solution is indicated for the prevention and treatment of hypokalemia presenting with or without metabolic alkalosis, in patients who have failed conservative management with potassium-rich foods or diuretic dose titrations. The injection form of potassium chloride is indicated to replenish potassium in patients who are not feasible candidates for oral potassium. Highly concentrated potassium is intended for the treatment of potassium deficiency in fluid restricted individuals who cannot tolerate fluid volumes normally associated with injected potassium solutions that contain lower concentrations.

Finally, the extended-release tablet preparation of potassium chloride is used to treat hypokalemia with or without metabolic alkalosis, to treat digitalis intoxication, and to manage patients with hypokalemic familial periodic paralysis. It is also used in the prevention of hypokalemia in those who are at a high risk of negative clinical outcomes if hypokalemia occurs; patients on digitalis or those with cardiac arrhythmias would be at particular risk of negative outcomes.

Potassium chloride with dextrose and sodium chloride

This liquid preparation is is indicated in a clinical setting as a source of water, calories and electrolytes. Potassium acetate solution is meant as an alternative to potassium chloride, replenishing potassium and added to large volume infusion fluids for intravenous injection.

Potassium citrate

The potassium citrate preparation is used for the management of renal tubular acidosis (RTA) with calcium stones (nephrolithiasis); calcium oxalate stones by any cause, and uric acid nephrolithiasis (with or without calcium stones). This regimen also includes adequate water intake (leading to a urine out put of 2 L/day or more) and sodium restriction.

Associated Conditions
Caloric Intake, Electrolyte and fluid balance conditions, Hydration, Hypokalemia, Potassium

Helicobacter Pylori Eradication and Follow-up

First Posted Date
2021-09-30
Last Posted Date
2021-09-30
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
4447
Registration Number
NCT05061732
Locations
🇨🇳

Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication

First Posted Date
2021-09-20
Last Posted Date
2023-07-19
Lead Sponsor
Shandong University
Target Recruit Count
1300
Registration Number
NCT05049902
Locations
🇨🇳

Maternity and Child Care Health Center of Dezhou, Dezhou, Shandong, China

🇨🇳

Heze Municipal 3rd people's hospital, Heze, Shandong, China

🇨🇳

Qilu hosipital, Jinan, Shandong, China

and more 3 locations

High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France

Active, not recruiting
Conditions
Atrial Fibrillation
Interventions
First Posted Date
2021-09-09
Last Posted Date
2025-04-16
Lead Sponsor
Pfizer
Target Recruit Count
1
Registration Number
NCT05038228
Locations
🇬🇧

Pfizer Investigator, London, United Kingdom

Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients

First Posted Date
2021-08-26
Last Posted Date
2021-09-14
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
504
Registration Number
NCT05023577
Locations
🇨🇳

Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Tetracycline Versus Doxycycline for HP Rescue Therapy

First Posted Date
2021-08-24
Last Posted Date
2021-08-26
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
242
Registration Number
NCT05018923
Locations
🇨🇳

Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

PPI-amoxicillin for H. Pylori Treatment

Phase 4
Conditions
Helicobacter Pylori Infection
Interventions
First Posted Date
2021-08-20
Last Posted Date
2021-08-23
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
732
Registration Number
NCT05014685
Locations
🇨🇳

Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Effectiveness and Safety of Different Antithrombotic Therapy for the Treatment of Ventricular Thrombus

Recruiting
Conditions
Ventricular Thrombus
Interventions
First Posted Date
2021-08-16
Last Posted Date
2023-03-02
Lead Sponsor
China National Center for Cardiovascular Diseases
Target Recruit Count
480
Registration Number
NCT05006677
Locations
🇨🇳

Qing Yang, Beijing, China

Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma

Phase 3
Recruiting
Conditions
Gastric Cancer
Interventions
Drug: PD-1 inhibitor
Radiation: Radiotherapy
Drug: Chemotherapy
First Posted Date
2021-08-10
Last Posted Date
2021-08-10
Lead Sponsor
Fudan University
Target Recruit Count
433
Registration Number
NCT04997837
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Efficacy of Canrenone as add-on Treatment in Moderate to Severe ARDS in COVID-19

Phase 2
Conditions
COVID-19 Acute Respiratory Distress Syndrome
Interventions
First Posted Date
2021-07-27
Last Posted Date
2022-05-20
Lead Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Target Recruit Count
180
Registration Number
NCT04977960

Matching Perfusion and Metabolic Activity in HFpEF

Phase 2
Recruiting
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
First Posted Date
2021-06-04
Last Posted Date
2025-02-19
Lead Sponsor
University of Pennsylvania
Target Recruit Count
53
Registration Number
NCT04913805
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath